Cargando…

Resistin-like beta reduction is associated to low survival rate and is downregulated by adjuvant therapy in colorectal cancer patients

Colorectal Cancer (CRC) is one of the most common cancers accounting for 1.8 million new cases worldwide every year. Therefore, the identification of new potential therapeutic targets represents a continuous challenge to improve survival and quality of CRC patient’s life. We performed a microarray a...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Rosa, Michelino, Di Cataldo, Antonio, Broggi, Giuseppe, Caltabiano, Rosario, Tibullo, Daniele, Castrogiovanni, Paola, Imbesi, Rosa, Lanteri, Raffaele, Salomone, Federico, Raciti, Giuseppina, Li Volti, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883247/
https://www.ncbi.nlm.nih.gov/pubmed/36707698
http://dx.doi.org/10.1038/s41598-023-28450-1
_version_ 1784879467519279104
author Di Rosa, Michelino
Di Cataldo, Antonio
Broggi, Giuseppe
Caltabiano, Rosario
Tibullo, Daniele
Castrogiovanni, Paola
Imbesi, Rosa
Lanteri, Raffaele
Salomone, Federico
Raciti, Giuseppina
Li Volti, Giovanni
author_facet Di Rosa, Michelino
Di Cataldo, Antonio
Broggi, Giuseppe
Caltabiano, Rosario
Tibullo, Daniele
Castrogiovanni, Paola
Imbesi, Rosa
Lanteri, Raffaele
Salomone, Federico
Raciti, Giuseppina
Li Volti, Giovanni
author_sort Di Rosa, Michelino
collection PubMed
description Colorectal Cancer (CRC) is one of the most common cancers accounting for 1.8 million new cases worldwide every year. Therefore, the identification of new potential therapeutic targets represents a continuous challenge to improve survival and quality of CRC patient’s life. We performed a microarray analysis dataset consisting of colon biopsies of healthy subjects (HS) and CRC patients. These results were further confirmed in a clinical setting evaluating a series of CRC patients to assess the expression of Resistin-Like Beta (RETNLB) and to correlate it with their clinical data. Our results showed a significant reduction of RETNLB expression in CRC biopsies compared to the HS mucosa. Furthermore, such reduction was significantly associated with the TNM grade and patients’ age. Furthermore, a significantly positive correlation was found within mutated subjects for KRAS, TP53, and BRAF. In particular, patients with poor prognosis at 5 years exhibited RETNLB lower levels. In-silico analysis data were confirmed by histochemical analysis in a series of CRC patients recruited by our group. The results obtained provided that RETNLB low levels are associated with an unfavorable prognosis in CRC patients and its expression is also dependent on adjuvant therapy. Further studies are warranted in order to evaluate the molecular mechanisms underlying the role of RETNLB in CRC progression.
format Online
Article
Text
id pubmed-9883247
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-98832472023-01-29 Resistin-like beta reduction is associated to low survival rate and is downregulated by adjuvant therapy in colorectal cancer patients Di Rosa, Michelino Di Cataldo, Antonio Broggi, Giuseppe Caltabiano, Rosario Tibullo, Daniele Castrogiovanni, Paola Imbesi, Rosa Lanteri, Raffaele Salomone, Federico Raciti, Giuseppina Li Volti, Giovanni Sci Rep Article Colorectal Cancer (CRC) is one of the most common cancers accounting for 1.8 million new cases worldwide every year. Therefore, the identification of new potential therapeutic targets represents a continuous challenge to improve survival and quality of CRC patient’s life. We performed a microarray analysis dataset consisting of colon biopsies of healthy subjects (HS) and CRC patients. These results were further confirmed in a clinical setting evaluating a series of CRC patients to assess the expression of Resistin-Like Beta (RETNLB) and to correlate it with their clinical data. Our results showed a significant reduction of RETNLB expression in CRC biopsies compared to the HS mucosa. Furthermore, such reduction was significantly associated with the TNM grade and patients’ age. Furthermore, a significantly positive correlation was found within mutated subjects for KRAS, TP53, and BRAF. In particular, patients with poor prognosis at 5 years exhibited RETNLB lower levels. In-silico analysis data were confirmed by histochemical analysis in a series of CRC patients recruited by our group. The results obtained provided that RETNLB low levels are associated with an unfavorable prognosis in CRC patients and its expression is also dependent on adjuvant therapy. Further studies are warranted in order to evaluate the molecular mechanisms underlying the role of RETNLB in CRC progression. Nature Publishing Group UK 2023-01-27 /pmc/articles/PMC9883247/ /pubmed/36707698 http://dx.doi.org/10.1038/s41598-023-28450-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Di Rosa, Michelino
Di Cataldo, Antonio
Broggi, Giuseppe
Caltabiano, Rosario
Tibullo, Daniele
Castrogiovanni, Paola
Imbesi, Rosa
Lanteri, Raffaele
Salomone, Federico
Raciti, Giuseppina
Li Volti, Giovanni
Resistin-like beta reduction is associated to low survival rate and is downregulated by adjuvant therapy in colorectal cancer patients
title Resistin-like beta reduction is associated to low survival rate and is downregulated by adjuvant therapy in colorectal cancer patients
title_full Resistin-like beta reduction is associated to low survival rate and is downregulated by adjuvant therapy in colorectal cancer patients
title_fullStr Resistin-like beta reduction is associated to low survival rate and is downregulated by adjuvant therapy in colorectal cancer patients
title_full_unstemmed Resistin-like beta reduction is associated to low survival rate and is downregulated by adjuvant therapy in colorectal cancer patients
title_short Resistin-like beta reduction is associated to low survival rate and is downregulated by adjuvant therapy in colorectal cancer patients
title_sort resistin-like beta reduction is associated to low survival rate and is downregulated by adjuvant therapy in colorectal cancer patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883247/
https://www.ncbi.nlm.nih.gov/pubmed/36707698
http://dx.doi.org/10.1038/s41598-023-28450-1
work_keys_str_mv AT dirosamichelino resistinlikebetareductionisassociatedtolowsurvivalrateandisdownregulatedbyadjuvanttherapyincolorectalcancerpatients
AT dicataldoantonio resistinlikebetareductionisassociatedtolowsurvivalrateandisdownregulatedbyadjuvanttherapyincolorectalcancerpatients
AT broggigiuseppe resistinlikebetareductionisassociatedtolowsurvivalrateandisdownregulatedbyadjuvanttherapyincolorectalcancerpatients
AT caltabianorosario resistinlikebetareductionisassociatedtolowsurvivalrateandisdownregulatedbyadjuvanttherapyincolorectalcancerpatients
AT tibullodaniele resistinlikebetareductionisassociatedtolowsurvivalrateandisdownregulatedbyadjuvanttherapyincolorectalcancerpatients
AT castrogiovannipaola resistinlikebetareductionisassociatedtolowsurvivalrateandisdownregulatedbyadjuvanttherapyincolorectalcancerpatients
AT imbesirosa resistinlikebetareductionisassociatedtolowsurvivalrateandisdownregulatedbyadjuvanttherapyincolorectalcancerpatients
AT lanteriraffaele resistinlikebetareductionisassociatedtolowsurvivalrateandisdownregulatedbyadjuvanttherapyincolorectalcancerpatients
AT salomonefederico resistinlikebetareductionisassociatedtolowsurvivalrateandisdownregulatedbyadjuvanttherapyincolorectalcancerpatients
AT racitigiuseppina resistinlikebetareductionisassociatedtolowsurvivalrateandisdownregulatedbyadjuvanttherapyincolorectalcancerpatients
AT livoltigiovanni resistinlikebetareductionisassociatedtolowsurvivalrateandisdownregulatedbyadjuvanttherapyincolorectalcancerpatients